Daxor (NASDAQ:DXR) Shares Down 3.1% – Here’s What Happened

Daxor Corporation (NASDAQ:DXR) shares fell 3.1% during mid-day trading on Tuesday. The stock traded as low as $10.30 and last traded at $10.30. Approximately 2,859 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 45,186 shares. The stock had previously closed at $10.63.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Daxor in a report on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Daxor Stock Down 0.6%

The company has a 50-day simple moving average of $10.61 and a two-hundred day simple moving average of $10.39.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Crescent Grove Advisors LLC acquired a new stake in Daxor during the first quarter worth about $104,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in shares of Daxor in the first quarter valued at $245,000. Susquehanna International Group LLP boosted its position in shares of Daxor by 97.7% in the second quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock valued at $275,000 after acquiring an additional 13,411 shares during the period. Finally, Aristides Capital LLC bought a new stake in Daxor during the first quarter worth about $403,000. 1.34% of the stock is owned by institutional investors and hedge funds.

About Daxor

Daxor Corporation (NASDAQ: DXR) is a medical device company focused on blood-volume measurement and related diagnostic technologies. Its principal product is the BVA-100 Blood Volume Analyzer, which uses an analysis of a blood sample containing a tracer to measure a patient’s total blood volume, plasma volume and red blood cell volume.

The company’s technology is designed to help clinicians assess fluid status and guide treatment decisions in settings such as heart failure, critical care, surgery, trauma and dialysis.